Showing 7,321 - 7,340 results of 26,672 for search '(( 50 ((((ng decrease) OR (nn decrease))) OR (a decrease)) ) OR ( 50 ms decrease ))', query time: 0.90s Refine Results
  1. 7321
  2. 7322
  3. 7323

    Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
  4. 7324

    Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
  5. 7325

    Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
  6. 7326

    Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
  7. 7327

    Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
  8. 7328
  9. 7329
  10. 7330

    Gonadal development and sex ratios as a function of TL. by Frederic H. Martini (481487)

    Published 2013
    “…</p> <p>(b) Sex ratios (female:male) as a function of TL. Data were sorted into 50 mm TL intervals. …”
  11. 7331
  12. 7332

    Context and impact of elevated antisense expression levels in the Δ<i>rho</i> mutant. by Ulrike Mäder (205299)

    Published 2016
    “…Each annotated gene is represented by a point. There is a strong negative correlation between sense and antisense expression in the Δ<i>rho</i> mutant (Pearson correlation coefficient r = -0.73) that is also visible but much weaker in the wild-type (r = -0.30). …”
  13. 7333

    A) Perfusate oxygenation (ΔPO) during reperfusion by Niels Dreyer (42388)

    Published 2011
    “…After 50 minutes, ΔPOdecreased in untreated lungs compared to baseline. …”
  14. 7334
  15. 7335

    Heatmaps with different genetic linkage and migration rate. by Georg Oberhofer (3401438)

    Published 2021
    “…<p>Heatmaps showing the average <i>Rescue</i> frequency for 100 <b>(A-C)</b> and 300 generations <b>(D-F)</b>. Linkage ranging from 0–50 cM, migration rate from 0.1–20% per generation. …”
  16. 7336
  17. 7337

    Effects of Y-P30 on expression and phosphorylation of glutamate receptors, Src, and ERK. by Janine R. Neumann (6330863)

    Published 2019
    “…(A) Representative blot at DIV 20; per lane, 50% of a lysate from a vehicle-treated control and a 60 min Y-P30-treated OTC was loaded on the left and the right side of a gel. …”
  18. 7338
  19. 7339
  20. 7340

    Participant characteristics. by Ronald Kusolo (13200268)

    Published 2025
    “…The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”